A phase III clinical trial is currently being conducted (NCT04338399) in which PI3K inhibitor buparlisib is administered with paclitaxel in patients with recurrent or metastatic HNSCC. The gene discussed is PIK3CA; the disease is head and neck squamous cell carcinoma.